论文部分内容阅读
目的:研究复方苦参注射液辅助TP方案治疗晚期卵巢肿瘤患者的临床疗效及其对患者免疫功能的影响。方法:选取106例晚期卵巢肿瘤患者为研究对象,按随机数字表法分为TP组和联合组,每组各53例。TP方案组患者采用顺铂+紫杉醇化疗,联合组患者采用复方苦参注射液辅助顺铂+紫杉醇化疗,比较两组患者的临床疗效。结果:联合组患者CR、RR率(56.60%、84.91%)显著高于对照组(P<0.05);联合组患者治疗后白细胞、T淋巴细胞亚群中CD3、CD4、CD8水平均显著高于TP组(P<0.05),差异均具有统计学意义。结论:复方苦参注射液辅助TP方案治疗晚期卵巢肿瘤患者可在提高化疗效果的同时对患者免疫功能不造成影响,具有较高的临床应用价值。
Objective: To study the clinical efficacy of Compound Kushen Injection-assisted TP in the treatment of advanced ovarian cancer patients and its effect on immune function. Methods: One hundred and sixty patients with advanced ovarian cancer were selected as study subjects and divided into TP group and combination group according to random number table. Each group had 53 cases. Patients in the TP regimen were treated with cisplatin plus paclitaxel. Patients in the combined group received Compound Kushen Injection for cisplatin plus paclitaxel chemotherapy, and the clinical efficacy was compared between the two groups. Results: The CR and RR rates in the combined group were significantly higher than those in the control group (56.60%, 84.91%, P <0.05). The levels of CD3, CD4 and CD8 in leukocyte and T lymphocyte subsets in the combined group were significantly higher than those in the control group TP group (P <0.05), the differences were statistically significant. Conclusion: Compound Kushen injection-assisted TP regimen in the treatment of patients with advanced ovarian cancer can improve the efficacy of chemotherapy without affecting the immune function in patients with high clinical value.